Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Entero Therapeutics, Inc. (ENTO) had Normalized Income after Taxes of $-0.95M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-1.34M |
|
-- |
|
-- |
|
$0.82M |
|
$-0.82M |
|
$-0.13M |
|
$-0.95M |
|
$-0.95M |
|
$-0.95M |
|
$-0.95M |
|
$-1.26M |
|
|
Normalized Income after Taxes |
$-0.95M |
$-0.82M |
|
$-0.82M |
|
4.76M |
|
4.79M |
|
$-0.28 |
|
$-0.28 |
|
| Balance Sheet Financials | |
$83.46M |
|
-- |
|
$1.74M |
|
$85.20M |
|
$28.74M |
|
-- |
|
-- |
|
$28.74M |
|
$-5.22M |
|
$54.78M |
|
$56.46M |
|
4.77M |
|
| Cash Flow Statement Financials | |
$-0.82M |
|
-- |
|
$0.70M |
|
$0.18M |
|
$0.07M |
|
$-0.12M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.90 |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-0.82M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
18.17% |
|
-1.73% |
|
-1.11% |
|
-1.68% |
|
$11.85 |
|
$-0.17 |
|
$-0.17 |
|